Gilead Sciences, Inc.





Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
65.06 USD +3.62% Intraday chart for Gilead Sciences, Inc. +0.56% -19.69%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup DJ
EU regulator mandates label updates on CAR-T cancer therapies RE
Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta MT
Transcript : Gilead Sciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer MT
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA MT
Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study CI
Transcript : Gilead Sciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial MT
Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis, A Rare, Chronic Inflammatory Liver Disease CI
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit MT
Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma MT
Kite?S Tecartus® Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia CI
Kite Announces Data from A Pilot Study in Collaboration with Dana-Farber Cancer Institute CI
Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise MT
Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer CI
Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as A First-Line Treatment for Upper GI Cancers CI
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival RE
Gilead Sciences Says Phase 3 Study Shows Trodelvy Cut Risk of Death by 16% in Non-Small Cell Lung Cancer Patients MT
Disaster averted Our Logo
Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study CI
Gilead Sciences Says Phase 3 Trial in Urothelial Cancer Misses Primary Target MT
Gilead's Trodelvy fails to meet main goal in late-stage study RE
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
65.06 USD
Average target price
82.7 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Gilead Sciences Completes $4.3 Billion Cymabay Acquisition
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.